[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335680-105":59,"doc-detail-335680-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","covid-19sensitive-tumour-response-2-year-assessment-of-the-sars-cov-2-humoral-response-in-cancer-patients-in-oncology-hospital-in-poland","COVID‑19–sensitive tumour response - 2-year assessment - of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland","","Vaccination is treated as the most important defence against viral infections, including SARS‑CoV‑2, and vaccines show effectiveness in oncological patients. At the same time, the cancer process can shape the magnitude of the humoral response, particularly in individuals after SARS‑CoV‑2 infection. The study examines how much COVID‑19 affects the “natural” anticancer-related defence potential, and whether a stronger antiviral response may explain asymptomatic infection in some patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/covid-19sensitive-tumour-response-2-year-assessment-of-the-sars-cov-2-humoral-response-in-cancer-patients-in-oncology-hospital-in-poland/335680/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/covid-19sensitive-tumour-response-2-year-assessment-of-the-sars-cov-2-humoral-response-in-cancer-patients-in-oncology-hospital-in-poland/335680.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study?","Question",{"text":112,"@type":113},"To assess how the cancer process impacts the humoral response in oncological patients who were vaccinated against SARS‑CoV‑2 and in those after COVID‑19.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many participants and antibody samples were analyzed over 2 years?",{"text":117,"@type":113},"One thousand six hundred and sixty-eight people were observed, and 5,082 SARS‑CoV‑2 IgG and IgM antibody samples were determined over two years.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results indicate about humoral response across patient groups?",{"text":121,"@type":113},"The results indicate a naturally more significant humoral response in oncological patients who had not been vaccinated and had not undergone anticancer therapy such as radiotherapy, chemotherapy, or surgical intervention, with response magnitude varying by cancer type.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335680,1790127262,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Immunology, Immunotherapy (2025) 74:27 [https://doi.org/10.1007/s00262-024-03895-z](https://doi.org/10.1007/s00262-024-03895-z)  \nCOVID‑19–sensitive tumour response: 2‑year assessment  \nof the SARS‑CoV‑2 humoral response in cancer patients in oncology hospital in Poland  \nPiotr Kosiorek1,2 · Bożena Mikołuć3 · Samuel Stróż2 · Anna Hryniewicz4 · Dorota E. Kazberuk5 · Robert Milewski6 · Anna Grzeszczuk7 · Magdalena J. Borkowska5 · Anna Stasiak‐Barmuta2  \nReceived: 12 September 2024 / Accepted: 13 November 2024 / Published online: 21 December 2024 © The Author(s) 2024  \nAbstract  \nVaccination has been considered the most crucial defence against viral infections, including SARS-CoV-2 . Numerous reports have demonstrated the effectiveness of the above vaccines in oncological patients. It has also been proven that, apart from vaccinations and oncological therapy, the course of the cancer process itself influences the magnitude of the humoral response, especially in people after infection with SARS-CoV-2 . The phenomenon we observe seems to confirm the presence of a \"natural\" defence potential in a cancer patient's body, in this case, directed against infection with a viral pathogen. A \"stronger\" antiviral response also explains the asymptomatic course of SARS-CoV-2 infection in some of the above patients. To what extent the SARS-CoV-2 infection weakened the \"natural\" potential of the anticancer response in these patients remains an open question.  \nObjective This study aimed to answer the question about the impact of the cancer process on the humoral response in oncological patients vaccinated against SARS-CoV-2 infection and in patients after COVID-19 .  \nMaterial and methods One thousand six hundred and sixty-eight people were observed. Over 2 years, 5,082 SARS-CoV-2 IgG and IgM antibody samples were determined. The concentration of antibodies was assessed in groups of oncological patients: those undergoing anticancer therapy after contracting COVID-19 and those after vaccination against the SARSCoV-2 infection.  \nResults The obtained results indicate a naturally more significant humoral response in oncological patients who have not been vaccinated and have not undergone anticancer therapy, such as radiotherapy, chemotherapy, or surgical intervention. The above observation applies to patients with breast, lung, colon, kidney, and testicular cancer, although the response varies significantly depending on the type of cancer.  \n* Piotr Kosiorek[pkosiorek@onkologia.bialystok.pl](pkosiorek@onkologia.bialystok.pl); [piotr.kosiorek@umb.edu.pl](piotr.kosiorek@umb.edu.pl)  \nBożena Mikołuć  \n[bozena.mikoluc@udsk.pl](bozena.mikoluc@udsk.pl)  \nSamuel Stróż  \n[samuel.stroz@ds.umb.edu.pl](samuel.stroz@ds.umb.edu.pl)  \nAnna Hryniewicz  \n[anna.hryniewicz@umb.edu.pl](anna.hryniewicz@umb.edu.pl)[ ](anna.hryniewicz@umb.edu.pl)Dorota E. Kazberuk [dkazberuk@onkologia.bialystok.pl](dkazberuk@onkologia.bialystok.pl)[ ](dkazberuk@onkologia.bialystok.pl)Robert Milewski [robert.milewski@umb.edu.pl](robert.milewski@umb.edu.pl)[ ](robert.milewski@umb.edu.pl)Anna Grzeszczuk  \n[anna.grzeszczuk@umb.edu.pl](anna.grzeszczuk@umb.edu.pl)[ ](anna.grzeszczuk@umb.edu.pl)[Magdalena J. Borkowska](Magdalena J. Borkowska)[mborkowska@onkologia.bialystok.pl](mborkowska@onkologia.bialystok.pl)  \nAnna Stasiak‐Barmuta  \n[anna.barmuta@umb.edu.pl](anna.barmuta@umb.edu.pl)  \n1 Department of Emergency, Maria Sklodowska‐Curie Bialystok Oncology Centre, Białystok, Poland  \n2 Department of Clinical Immunology, Medical University of Białystok, Białystok, Poland  \n3 Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Bialystok, Poland  \n4 Department of Rehabilitation, Medical University of Białystok, Białystok, Poland  \n5 Department of Radiotherapy, Maria Sklodowska‐Curie Bialystok Oncology Centre, Białystok, Poland  \n6 Department of Biostatistics and Medical Informatics, Medical University of Białystok, Białystok, Poland  \n7 Department of Infectious D","cbCaiptXlaBe1Q2L","https://ap.wps.com/l/cbCaiptXlaBe1Q2L","pdf",2963968,13,"English","# Abstract\n## Objective\n## Material and methods\n## Results\n# Introduction\n## Immune response and asymptomatic infection\n## Antibody response during therapy","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To assess how the cancer process impacts the humoral response in oncological patients who were vaccinated against SARS‑CoV‑2 and in those after COVID‑19.\"},{\"question\":\"How many participants and antibody samples were analyzed over 2 years?\",\"answer\":\"One thousand six hundred and sixty-eight people were observed, and 5,082 SARS‑CoV‑2 IgG and IgM antibody samples were determined over two years.\"},{\"question\":\"What did the results indicate about humoral response across patient groups?\",\"answer\":\"The results indicate a naturally more significant humoral response in oncological patients who had not been vaccinated and had not undergone anticancer therapy such as radiotherapy, chemotherapy, or surgical intervention, with response magnitude varying by cancer type.\"}]","COVID‑19–sensitive tumour response - 2-year assessment - of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland | PDF",1790011915,33]